Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sound waves vs. pancreatic cancer: a new way to attack deadly tumours

NCT ID NCT07873606

Disease control Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 14, 2026 · Last updated Oct 15, 2026 · Updated 1 time

Summary

Researchers are testing a non-invasive ultrasound technique called histotripsy in people with pancreatic cancer that cannot be removed by surgery. Histotripsy uses focused sound waves to create tiny bubbles inside the tumour that burst and break apart the cancer tissue without heat or radiation. The study will track safety, changes in tumour size, and pain levels in 20 participants. Scientists also want to see whether the treatment triggers an immune response that could make other cancer therapies work better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
histotripsy, a non-invasive ultrasound procedure that uses sound waves to break down tumour tissue
What this could lead to
If it works, histotripsy could offer a way to destroy pancreatic tumours without surgery or heat, and might help the immune system fight the cancer alongside chemotherapy.
What could go wrong
This is a small, early study of 20 people with a hard-to-treat cancer. The procedure may not control tumours well enough, and it carries risks from general anaesthesia and possible damage to nearby organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old * Fit for general anaesthesia * Unresectable pancreatic cancer with, or without vascular encasement * With or without distant metastasis * Without portal vein thrombosis * Good performance status: 1. Tumour visible and targetable by ultrasound with acceptable acoustic windows 2. Adequate hematologic, hepatic, and renal function Exclusion Criteria: * Refusal to take part in clinical trial * Portal vein thrombosis present * Not fit for general anaesthesia * Poor general condition with limited life expectancy * Uncontrolled coagulopathy * Extensive bowel interposition preventing safe targeting, per recent porcine safety data linking mis-targeting to bowel injury

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic ductal adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreas disorder pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic tumours

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The University of Hong Kong

    RECRUITING

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.